Citations

Clear

16281 citation(s) found for "Yu, David".

Fat mass and obesity gene and cognitive decline
Bressler, Jan , Fornage, Myriam , Demerath, Ellen W. , Monda, Keri L., Penman, Alan D. , Boerwinkle, Eric , Knopman, David S. , North, Kari E. , Mosley, Thomas H.

Mayo Clinic

Neurology | November 8, 2012 | Volume: 80 | Issue: 1 | Pages: 92-99

10.1212/wnl.0b013e3182768910 | PMID 23136261 Get It

Mechanism of Loss of Kv11.1 K + Current in Mutant T421M-Kv11.1–Expressing Rat Ventricular Myocytes
Balijepalli, Sadguna Y., Lim, Evi , Concannon, Sarah P., Chew, Chen Li, Holzem, Kassandra E., Tester, David J. , Ackerman, Michael J. , Delisle, Brian P. , Balijepalli, Ravi C. , January, Craig T.

Mayo Clinic

Circulation | November 7, 2012 | Volume: 126 | Issue: 24 | Pages: 2809-2818

10.1161/circulationaha.112.118018 | PMID 23136156 Get It

Background— Type 2 long QT syndrome involves mutations in the human ether a-go-go–related gene ( hERG or KCNH2 ). T421M, an S1 domain mutation in the Kv11.1 channel protein, was identified in a resuscitated patient. We assessed its biophysical, protein trafficking, and pharmacological mechanisms in adult rat ventricular myocytes. Methods and Results— Isolated adult rat ventricular myocytes were infected with wild-type (WT)–Kv11.1– and T421M-Kv11.1–expressing adenovirus and analyzed with the use of patch clamp, Western blot, and confocal imaging techniques. Expression of WT-Kv11.1 or T421M-Kv11.1 produced peak tail current ( I Kv11.1 ) of 8.78±1.18 and 1.91±0.22 pA/pF, respectively. Loss of mutant I Kv11.1 resulted from (1) a partially trafficking-deficient channel protein with reduced cell surface expression and (2) altered channel gating with a positive shift in the voltage dependence of activation and altered kinetics of activation and deactivation. Coexpression of WT+T421M-Kv11.1 resulted in heterotetrameric channels that remained partially trafficking deficient with only a minimal increase in peak I Kv11.1 density, whereas the voltage dependence of channel gating became WT-like. In the adult rat ventricular myocyte model, both WT-Kv11.1 and T421M-Kv11.1 channels responded to β-adrenergic stimulation by increasing I Kv11.1 . Conclusions— The T421M-Kv11.1 mutation caused a loss of I Kv11.1 through interactions of abnormal protein trafficking and channel gating. Furthermore, for coexpressed WT+T421M-Kv11.1 channels, different dominant-negative interactions govern protein trafficking and ion channel gating, and these are likely to be reflected in the clinical phenotype. Our results also show that WT and mutant Kv11.1 channels responded to β-adrenergic stimulation.
Augmented Reality Image Guidance Improves Navigation for Beating Heart Mitral Valve Repair
Chu, Michael , Moore, John , Peters, Terry M. , Bainbridge, Daniel , McCarty, David, Guiraudon, G, Wedlake, Chris, Lang, Pencilla , Rajchl, Martin , Currie, Maria , Daly, Richard C. , Kiaii, Bob, Chu, Michael W A

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | November 2, 2012 | Volume: 7 | Issue: 4 | Pages: 274-281

10.1097/imi.0b013e31827439ea | PMID 23123995 Get It

Objective Emerging off-pump beating heart valve repair techniques offer patients less invasive alternatives for mitral valve (MV) repair. However, most of these techniques rely on the limited spatial and temporal resolution of transesophageal echocardiography (TEE) alone, which can make tool visualization and guidance challenging. Methods Using a magnetic tracking system and integrated sensors, we created an augmented reality (AR) environment displaying virtual representations of important intracardiac landmarks registered to biplane TEE imaging. In a porcine model, we evaluated the AR guidance system versus TEE alone using the transapically delivered NeoChord DS1000 system to perform MV repair with chordal reconstruction. Results Successful tool navigation from left ventricular apex to MV leaflet was achieved in 12 of 12 and 9 of 12 (P = 0.2) attempts with AR imaging and TEE alone, respectively. The distance errors of the tracked tool tip from the intended midline trajectory (5.2 ± 2.4 mm vs 16.8 ± 10.9 mm, P = 0.003), navigation times (16.7 ± 8.0 seconds vs 92.0 ± 84.5 seconds, P = 0.004), and total path lengths (225.2 ± 120.3 mm vs 1128.9 ± 931.1 mm, P = 0.003) were significantly shorter in the AR-guided trials compared with navigation with TEE alone. Furthermore, the potential for injury to other intracardiac structures was nearly 40-fold lower when using the AR imaging for tool navigation. The AR guidance also seemed to shorten the learning curve for novice surgeons. Conclusions Augmented reality–enhanced TEE facilitates more direct and safe intracardiac navigation of the NeoChord DS tool from left ventricular apex to MV leaflet. Tracked tool path results demonstrate fourfold improved accuracy, fivefold shorter navigation times, and overall improved safety with AR imaging guidance.
A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants
Sharma, Manu , Aasly, Jan , Annesi, Grazia , Brice, Alexis , Bozi, Maria , Barcikowska, Maria , Crosiers, David , Clarke, Carl E , Facheris, Maurizio , Farrer, Matthew J. , Garraux, Gaëtan , Gispert, Suzana, Auburger, Georg , Vilariño‐Güell, Carles , Hicks, Andrew A. , Hattori, Nobutaka , Jeon, Beom S., Jamrozik, Zygmunt , Krygowska‐Wajs, Anna, Lesage, Suzanne , Lill, Christina M. , Lin, Juei‐Jueng , Lynch, Timothy , Lichtner, Peter , Lang, Anthony E. , Libioulle, Cécile , Murata, Miho, Mok, Vincent , Jasińska‐Myga, Barbara, Mellick, George D. , Morrison, Karen , Meitnger, Thomas, Zimprich, Alexander , Opala, Grzegorz, Pramstaller, Peter P. , Pichler, Irene , Park, Sung Sup , Quattrone, Aldo , Ross, Owen A. , Stockton, Joanne , Satake, Wataru , Silburn, Peter A., Strom, Tim M., Theuns, Jessie , Tan, Eng King, Tomiyama, Hiroyuki , Uitti, Ryan J. , Broeckhoven, Christine Van , Wirdefeldt, Karin , Xiromerisiou, Georgia , Yomono, Harumi, Yueh, Kuo-Chu, Zhao, Yi , Gasser, Thomas , Maraganore, Demetrius M. , Krüger, Rejko , Ioannidis, John P. A. , Bertram, Lars , Hadjigeorgiou, Georgios M. , Rogaeva, Ekaterina A. , Stefanis, Leonidas , Toda, Tatsushi , Wszołek, Zbigniew K. , Lang, Anthony E , Ross, Owen A , Zimprich, Alexander , Brice, Alexis

Mayo Clinic

Journal of Medical Genetics | November 2, 2012 | Volume: 49 | Issue: 11 | Pages: 721-726

10.1136/jmedgenet-2012-101155 | PMID 23125461 Get It

Background Two recent studies identified a mutation (p.Asp620Asn) in the vacuolar protein sorting 35 gene as a cause for an autosomal dominant form of Parkinson disease . Although additional missense variants were described, their pathogenic role yet remains inconclusive. Methods and results We performed the largest multi-center study to ascertain the frequency and pathogenicity of the reported vacuolar protein sorting 35 gene variants in more than 15,000 individuals worldwide. p.Asp620Asn was detected in 5 familial and 2 sporadic PD cases and not in healthy controls, p.Leu774Met in 6 cases and 1 control, p.Gly51Ser in 3 cases and 2 controls. Overall analyses did not reveal any significant increased risk for p.Leu774Met and p.Gly51Ser in our cohort. Conclusions Our study apart from identifying the p.Asp620Asn variant in familial cases also identified it in idiopathic Parkinson disease cases, and thus provides genetic evidence for a role of p.Asp620Asn in Parkinson disease in different populations worldwide.
Migraine headache is present in the aura phase
Hansen, Jakob Møller , Silberstein, Stephen D., Saper, Joel R., Aurora, Sheena K. , Goadsby, Peter J. , Charles, Andrew , Lipton, Richard B. , Dodick, David W. , Goadsby, Peter J , Charles, Andrew

Mayo Clinic

Neurology | November 1, 2012 | Volume: 79 | Issue: 20 | Pages: 2044-2049

10.1212/wnl.0b013e3182749eed | PMID 23115208 Get It

Design and Baseline Characteristics of Participants in a Phase III Randomized Trial of Celecoxib and Selenium for Colorectal Adenoma Prevention
Thompson, Patricia A. , Roe, Denise J. , Fales, Liane, Buckmeier, Julie A., Wang, Fang , Bhattacharyya, Achyut, Green, Sylvan, Hsu, Chiu‐Hsieh , Chow, H.‐H. Sherry , Ahnen, Dennis J. , Heigh, Russell I., Fay, David E., Jacobs, Elizabeth T. , Ashbeck, Erin L., Alberts, David S., Lance, Peter , Hamilton, Stanley R. , Boland, C. Richard , Martı́nez, Marı́a Elena

Mayo Clinic

Cancer Prevention Research | October 31, 2012 | Volume: 5 | Issue: 12 | Pages: 1381-1393

10.1158/1940-6207.capr-12-0204 | PMID 23060037 Get It

Abstract COX inhibitors reduce colorectal adenoma recurrence by up to 45% and selenium supplementation may prevent colorectal cancer. Following colonoscopic adenoma resection, 1,600 men and women, ages 40 to 80 years, were randomized to celecoxib (400 mg daily), a selective COX-2 inhibitor, and/or selenium (200 μg daily as selenized yeast), or double placebo. The trial was initiated in November 2001. The primary trial endpoint is adenoma recurrence in each intervention group compared with placebo, as determined by surveillance colonoscopy conducted three to five years after baseline. Randomization was stratified by use of low-dose aspirin (81 mg) and clinic site. Following reports of cardiovascular toxicity associated with COX-2 inhibitors, the celecoxib arm was discontinued in December 2004 when 824 participants had been randomized. Accrual continued with randomization to selenium alone or placebo. Randomization of the originally planned cohort (n = 1,621) was completed in November 2008. A further 200 patients with one or more advanced adenomas (denoting increased risk for colorectal cancer) were accrued to enhance statistical power for determining intervention efficacy in this higher-risk subgroup. Accrual of the total cohort (n = 1,824) was completed in January 2011. Baseline cohort characteristics include: mean age 62.9 years; 65% male; body mass index (BMI) 29.1 ± 5.1; 47% taking low-dose aspirin while on trial; 20% with three or more adenomas; and 38% with advanced adenomas. Intervention effects on adenoma recurrence will be determined, and their modification by genetic background and baseline selenium level. The effect of selenium supplementation on risk for type II diabetes will also be reported. Cancer Prev Res; 5(12); 1381–93. ©2012 AACR.
Navigating the Difficult Robotic Assisted Pyeloplasty
Thiel, David D.

Mayo Clinic

ISRN Urology | October 30, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-4

10.5402/2012/291235 | PMID 23213571 Get It

Pyeloplasty is the gold standard therapy for ureteropelvic junction obstruction. Robotic assisted pyeloplasty has been widely adopted by urologists with and without prior laparoscopic pyeloplasty experience. However, difficult situations encountered during robotic assisted pyeloplasty can significantly add to the difficulty of the operation. This paper provides tips for patient positioning, port placement, robot docking, and intraoperative dissection and repair in patients with the difficult situations of obesity, large floppy liver, difficult to reflect colon (transmesenteric pyeloplasty), crossing vessels, large calculi, and previous attempts at ureteropelvic junction repair. Techniques presented in this paper may aid in the successful completion of robotic assisted pyeloplasty in the face of the difficult situations noted above.
A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity
Guidugli, Lucia, Singh, Namit , Thompson, James E. , Erding, Catherine A., Engel, Christoph , Schmutzler, Rita K., Nathanson, Katherine L. , Radice, Paolo , Tonin, Patricia N. , Lindor, Noralane M. , Goldgar, David E., Pankratz, V. Shane , Domchek, Susan M. , Singer, Christian F. , Couch, Fergus J. , Thompson, James R. , Radice, Paolo , Nathanson, Katherine L , Engel, Christoph

Mayo Clinic

Cancer Research | October 30, 2012 | Volume: 73 | Issue: 1 | Pages: 265-275

10.1158/0008-5472.can-12-2081 | PMID 23108138 Get It

Abstract The relevance of many BRCA2 variants of uncertain significance (VUS) to breast cancer has not been determined due to limited genetic information from families carrying these alterations. Here, we classified six new variants as pathogenic or nonpathogenic by analysis of genetic information from families carrying 64 individual BRCA2 DNA binding domain (DBD) missense mutations using a multifactorial likelihood model of cancer causality. Next, we evaluated the use of a homology-directed DNA break repair (HDR) functional assay as a method for inferring the clinical relevance of VUS in the DBD of BRCA2 using 18 established nonpathogenic missense variants and all 13 established pathogenic missense mutations from the BRCA2 DBD. Compared with the known status of these variants based on the multifactorial likelihood model, the sensitivity of the HDR assay for pathogenic mutations was estimated at 100% [95% confidence interval (CI): 75.3%–100%] and specificity was estimated at 100% (95% CI: 81.5%–100%). A statistical classifier for predicting the probability of pathogenicity of BRCA2 DBD variants was developed using these functional results. When applied to 33 additional VUS, the classifier identified eight with 99% or more probability of nonpathogenicity and 18 with 99% or more probability of pathogenicity. Thus, in the absence of genetic evidence, a cell-based HDR assay can provide a probability of pathogenicity for all VUS in the BRCA2 DBD, suggesting that the assay can be used in combination with other information to determine the cancer relevance of BRCA2 VUS. Cancer Res; 73(1); 265–75. ©2012 AACR.
Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia
Geng, Huimin , Brennan, Sarah, Milne, Thomas A. , Chen, Wei‐Yi , Li, Yushan , Hurtz, Christian , Kweon, Soo-Mi, Zickl, Lynette, Shojaee, Seyedmehdi, Biswas, Debabrata, Yuan, Xin , Racevskis, Janis, Ketterling, Rhett P. , Luger, Selina M. , Tallman, Martin S. , Rowe, Jacob M. , Litzow, Mark R. , Allis, C. David, Müschen, Markus , Paietta, Elisabeth , Elemento, Olivier , Melnick, Ari , Neuberg, Donna , Huang, Chuanxin , Lazarus, Hillard M. , Guzmán, Mónica L. , Roeder, Robert G. , Melnick, Ari , Ketterling, Rhett P

Mayo Clinic

Cancer Discovery | October 30, 2012 | Volume: 2 | Issue: 11 | Pages: 1004-1023

10.1158/2159-8290.cd-12-0208 | PMID 23107779 Get It

Abstract Genetic lesions such as BCR–ABL1, E2A–PBX1, and MLL rearrangements (MLLr) are associated with unfavorable outcomes in adult B-cell precursor acute lymphoblastic leukemia (B-ALL). Leukemia oncoproteins may directly or indirectly disrupt cytosine methylation patterning to mediate the malignant phenotype. We postulated that DNA methylation signatures in these aggressive B-ALLs would point toward disease mechanisms and useful biomarkers and therapeutic targets. We therefore conducted DNA methylation and gene expression profiling on a cohort of 215 adult patients with B-ALL enrolled in a single phase III clinical trial (ECOG E2993) and normal control B cells. In BCR–ABL1-positive B-ALLs, aberrant cytosine methylation patterning centered around a cytokine network defined by hypomethylation and overexpression of IL2RA(CD25). The E2993 trial clinical data showed that CD25 expression was strongly associated with a poor outcome in patients with ALL regardless of BCR–ABL1 status, suggesting CD25 as a novel prognostic biomarker for risk stratification in B-ALLs. In E2A–PBX1-positive B-ALLs, aberrant DNA methylation patterning was strongly associated with direct fusion protein binding as shown by the E2A–PBX1 chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq), suggesting that E2A–PBX1 fusion protein directly remodels the epigenome to impose an aggressive B-ALL phenotype. MLLr B-ALL featured prominent cytosine hypomethylation, which was linked with MLL fusion protein binding, H3K79 dimethylation, and transcriptional upregulation, affecting a set of known and newly identified MLL fusion direct targets with oncogenic activity such as FLT3 and BCL6. Notably, BCL6 blockade or loss of function suppressed proliferation and survival of MLLr leukemia cells, suggesting BCL6-targeted therapy as a new therapeutic strategy for MLLr B-ALLs. Significance: We conducted the first integrative epigenomic study in adult B-ALLs, as a correlative study to the ECOG E2993 phase III clinical trial. This study links for the first time the direct actions of oncogenic fusion proteins with disruption of epigenetic regulation mediated by cytosine methylation. We identify a novel clinically actionable biomarker in B-ALLs: IL2RA(CD25), which is linked with BCR–ABL1 and an inflammatory signaling network associated with chemotherapy resistance. We show that BCL6 is a novel MLL fusion protein target that is required to maintain the proliferation and survival of primary human adult MLLr cells and provide the basis for a clinical trial with BCL6 inhibitors for patients with MLLr. Cancer Discov; 2(11); 1004–23. ©2012 AACR. Read the Commentary on this article by Cimmino and Aifantis, p. 976. This article is highlighted in the In This Issue feature, p. 961
Prevalence of buried Barrett’s metaplasia in patients before and after radiofrequency ablation
Yuan, Jay, Hernandez, Jeric, Ratuapli, Shiva K., Petris, Giovanni De , Lam‐Himlin, Dora , Burdick, George E., Pannala, Rahul , Ramirez, Francisco C. , Fleischer, David E., Ruff, Kevin

Mayo Clinic

Endoscopy | October 30, 2012 | Volume: 44 | Issue: 11 | Pages: 993-997

10.1055/s-0032-1325678 | PMID 23108770 Get It